Early-stage funding Sonnest, Inc. has secured a $4M Series A and remains a pre-clinical healthcare company, indicating a potential long sales cycle but ample strategic collaboration opportunities with early adopters in cardiology and medical imaging.

Heart imaging focus Electrast is designed for rapid, cost-effective myocardial perfusion imaging at the point of care without ionizing radiation, creating a strong value proposition for hospitals, cardiology clinics, and ER/ICU settings seeking safer imaging alternatives.

Targeted buyers Primary buyers are likely cardiology departments, imaging centers, and hospital procurement teams seeking innovative ultrasound-based diagnostics; consider partnerships with group purchasing organizations and clinical trial networks.

Clinical advantage The technology promises quick perfusion assessment and reduced exposure to toxic dyes, presenting a compelling case for clinicians aiming to improve throughput and patient safety, potentially accelerating procurement discussions.

Strategic collaborations Collaborations with Drexel University researchers and seasoned healthcare entrepreneurs suggest readiness for grant-backed pilots and sponsored studies; leverage these networks to pilot Electrast in academic medical centers and community hospitals.